dalbavancin
Selected indexed studies
- Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. (Clin Pharmacokinet, 2022) [PMID:34931283]
- Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review. (Int J Antimicrob Agents, 2023) [PMID:36758775]
- Dalbavancin. (Rev Esp Quimioter, 2021) [PMID:34598419]
_Worker-drafted node — pending editorial review._
Connections
dalbavancin is a side effect of
Sources
- Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. (2022) pubmed
- Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review. (2023) pubmed
- Dalbavancin. (2021) pubmed
- A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. (2025) pubmed
- Dalbavancin. (2008) pubmed
- Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review. (2022) pubmed
- Dalbavancin for the treatment of bone and joint infections: A meta-analysis. (2025) pubmed
- Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety. (2019) pubmed
- Dalbavancin: a review. (2007) pubmed
- Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. (2022) pubmed